Covid-19 testing drops even as daily cases rise to three-month high

Testing volumes have not grown much nationally, though individual states show some improvement

covid
A health worker testing for Covid-19 collects swab samples of residents in Gurugram on April 16, 2022. (PTI photo)
Sohini DasSachin P Mampatta Mumbai
4 min read Last Updated : Jun 09 2022 | 11:41 PM IST
Despite India’s daily Covid-19 cases touching a three-month high with 7,240 cases on Thursday, laboratory testing of the viral infection has not gained momentum.

Testing volumes have not grown much nationally, though individual states show some improvement.

An analysis of data from independent tracker covid19bharat.org shows that the national 7-day moving average number of tests has dropped 15.4 per cent from around 443,471 on May 15 to 375,145 on June 7 (see chart 1).

Also Read

There had been more than four times that number — as many as 1.7 million tests daily — in the early part of the year when cases had risen because of the Omicron variant. The states that are recording among the highest numbers are also the ones that have proactively stepped up testing even as the national testing numbers decline.

Maharashtra and Kerala have higher testing than was seen in mid-May (see chart 2).
Demand for home-testing through rapid antigen test (RAT) kits, however, is on the rise.

“We have seen an increase in demand for CoviSelf by 30-40 per cent in India in the last one month. We saw an uptick in demand from North around mid-May but now we are witnessing a rise in demand from West and South. We are the largest manufacturer of RAT kits with the capacity to produce 1.5 million test kits per day,” said Hasmukh Rawal of Pune-based Mylab Discovery Solutions.

Many home tests are not reported officially. All such kits are linked to a mobile application, which is linked to the back-end secure server of the Indian Council of Medical Research where any positive test data is captured and stored. However, since the test results are fairly easy to interpret, many often do not use the mobile application, and thus their results are not captured in the national database.

A Mumbai civic body official admitted that the actual Covid-19 positive numbers would be much higher than what are being captured through laboratory testing.
Private diagnostic labs say that they have seen some rise in demand for Covid-19 testing, but it is not significant.

“It has not reached the peak yet and it is not as high as the second or third wave. In comparison with Delta or Omicron, the volumes have not grown because of excessive home testing options that are available. Moreover, people are not willing to do the test themselves. We are observing a substantial increase in positive cases, especially in Mumbai. But most testing is happening via RATs where we are witnessing low to moderate symptoms,” said Ameera Shah, MD, Metropolis Healthcare.

Another large national diagnostic player, SRL, too said that testing has gone up in pockets — Kerala, Mumbai, some parts of Punjab. “As such, there is a 20 per cent rise in demand for PCR tests, but these are concentrated in pockets. At present, we are not collecting any government samples for processing,” said Anand K, CEO, SRL Diagnostics.

Anand added that the test positivity rate in laboratory settings is high — around 7-8 per cent — as mostly symptomatic cases are coming for tests.

Health secy writes to states

The Union health secretary has written to states to step up vigil and take pre-emptive actions, if necessary, to contain any rapid spread of Covid-19 infections. Union Health Secretary Rajesh Bhushan said in his letter that in the week ending June 8,4,207 average daily new cases were reported, compared to 2,663 cases in the week ending June 1.

The health ministry has asked states to ensure a high level of testing, and monitor average daily tests per million as well as share of RT-PCR in the overall tests.

The ministry has asked states to ensure Covid-19 appropriate behaviour among people, monitor clusters of Covid-19 cases and influenza-like illnesses, as well as genomic sequencing of samples from international passengers and clusters of cases.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronaviruspublic healthHealth MinistryCoronavirus TestsTop business storieshealth newsInventia Healthcare

Next Story